Ajlan Atasoy

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · New England Journal of Medicine · 2020 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +15

Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC

Yi‐Long Wu, Thomas John, Christian Grohé et al. · Journal of Thoracic Oncology · 2021 · 151 citations · Full text

Medicine, Oncology, Pharmacology +14

Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer

Michael A. Morse, Michael J. Overman, Leighanne Hartman et al. · The Oncologist · 2019 · 117 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.

Heinz‐Josef Lenz, Sara Lonardi, Vittorina Zagonel et al. · Journal of Clinical Oncology · 2020 · 60 citations

Medicine, Oncology, Pharmacotherapy +17

Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2019 · 39 citations

Medicine, Oncology, Pharmacotherapy +14